Corcept Therapeutics INC Form 4 insider transactions

Chief Development Officer William Guyer acquired 1,754 shares of Corcept Therapeutics common stock through an incentive plan.

Corcept Therapeutics President Sean Maduck exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Corcept Therapeutics CFO Atabak Mokari exercised options and sold 40,000 shares of common stock under a 10b5-1 trading plan.

Chief Business Officer Gary Charles Robb reported recent acquisitions and tax-related dispositions of Corcept Therapeutics common stock.

Corcept Therapeutics CEO Joseph K. Belanoff reported transactions involving company stock, including acquisitions and a sale executed under a Rule 10b5-1 plan.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, sold 5,000 shares of common stock.

Corcept Therapeutics President Sean Maduck exercised 75,000 stock options and sold 75,000 shares under a 10b5-1 trading plan.

Director James N. Wilson reported a series of internal share transfers between family trusts and partnerships.

Corcept Therapeutics Director Leonard G. Baker Jr. acquired 12,500 stock options on May 21, 2026, as detailed in a Form 4 filing.

Director Gregg H. Alton of Corcept Therapeutics acquired 12,500 stock options with an exercise price of $59.69, vesting over one year.

Director James N. Wilson acquired 12,500 stock options in Corcept Therapeutics Inc. on May 21, 2026.

Corcept Therapeutics Director Daniel N. Swisher Jr. acquired 12,500 stock options on May 21, 2026, as detailed in a recent SEC Form 4 filing.

Corcept Therapeutics Director Joshua M. Murray acquired 12,500 stock options with an exercise price of $59.69, vesting over one year.

David L. Mahoney, a Director at Corcept Therapeutics, acquired stock options for 12,500 shares.

Corcept Therapeutics Director Kimberly Park acquired 12,500 stock options with an exercise price of $59.69, vesting over one year.

Chief Business Officer Gary Charles Robb reported a series of stock gifts and trust transfers involving Corcept Therapeutics common stock.

Corcept Therapeutics Director James N. Wilson reported a gift of 2,000 shares of common stock.

Corcept Therapeutics Chief Development Officer William Guyer executed a series of transactions involving company stock, including the acquisition of stock options and the sale of common stock.

Corcept Therapeutics Director James N. Wilson reported the acquisition of 5,000 shares of common stock on April 6, 2026.

Corcept Therapeutics CEO Joseph K. Belanoff sold 26,198 shares of common stock for approximately $1.31 million under a pre-arranged 10b5-1 trading plan.

Corcept Therapeutics Director James N. Wilson reported gifting 4,000 shares of common stock as part of a routine transaction.

Corcept Therapeutics' Chief Development Officer, William Guyer, exercised stock options and subsequently sold an equal number of common shares under a pre-arranged 10b5-1 plan.

Corcept Therapeutics Director and 10% Owner G. Leonard Baker Jr. acquired 100,000 shares of common stock for approximately $3.3 million through pre-planned transactions.

Corcept Therapeutics Director James N. Wilson reported a planned gift of 28,000 common shares effective March 13, 2026, executed under a Rule 10b5-1 trading plan.

Corcept Therapeutics Director David L. Mahoney exercised stock options and subsequently transferred shares to a family trust, with some shares withheld for tax obligations.

Corcept Therapeutics' Chief Accounting & Technology Officer, Joseph Douglas Lyon, increased his direct beneficial ownership of common stock through a purchase plan and restricted stock awards, while also having shares withheld for tax obligations.

Corcept Therapeutics' President of Endocrinology, Sean Maduck, reported recent acquisitions of common stock through a purchase plan and restricted stock awards, alongside a tax-related disposition.

Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, reported the acquisition of 499 common shares and 499 unvested restricted stock awards, alongside a tax-related share withholding.

Corcept Therapeutics' Chief Development Officer, William Guyer, increased his direct ownership through a share purchase and restricted stock awards.

Corcept Therapeutics CFO Atabak Mokari increased his direct beneficial ownership through a purchase plan and restricted stock awards, while also disposing of shares for tax obligations.